Back to top
more

Jazz Pharmaceuticals (JAZZ)

(Delayed Data from NSDQ)

$224.66 USD

224.66
1,906,786

-2.27 (-1.00%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $224.54 -0.12 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

by Zacks Equity Research

ALKS' phase II Vibrance-3 study investigates the safety and efficacy of ALKS 2680 versus placebo for treating adults with idiopathic hypersomnia.

Zacks Equity Research

VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates

by Zacks Equity Research

Vertex plans to submit regulatory filings seeking approval for zimislecel in type 1 diabetes in 2026. However, it is likely to stop further development of VX-264.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

JAZZ or ARGX: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

JAZZ vs. ARGX: Which Stock Is the Better Value Option?

Zacks Equity Research

BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance

by Zacks Equity Research

The FDA clears Beam Therapeutics' investigational new drug application for BEAM-302 for the treatment of alpha-1 antitrypsin deficiency in the United States.

Zacks Equity Research

NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication

by Zacks Equity Research

The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.

Zacks Equity Research

Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint

by Zacks Equity Research

Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.

Zacks Equity Research

Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride

by Zacks Equity Research

MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride have been highlighted in this Screen of The Week article.